NasdaqGS - Nasdaq Real Time Price • USD
Royalty Pharma plc (RPRX)
As of 3:11 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 7 | 7 |
| Avg. Estimate | 0.97 | 0.96 | 3.94 | 4.39 |
| Low Estimate | 0.92 | 0.88 | 3.68 | 4.1 |
| High Estimate | 1.06 | 1.04 | 4.2 | 4.67 |
| Year Ago EPS | 0.84 | 0.79 | 4.5 | 3.94 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 7 | 7 |
| Avg. Estimate | 616.15M | 661.83M | 2.61B | 2.87B |
| Low Estimate | 577.19M | 556.78M | 2.34B | 2.54B |
| High Estimate | 681.01M | 724.55M | 2.76B | 3.12B |
| Year Ago Sales | -- | 536.31M | 2.35B | 2.61B |
| Sales Growth (year/est) | -- | 23.40% | 10.70% | 10.00% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 0.81 | 0.76 | 1.01 | 0.98 |
| EPS Actual | 0.84 | 0.79 | 1.15 | 0.98 |
| Difference | 0.03 | 0.03 | 0.14 | 0 |
| Surprise % | 3.70% | 3.90% | 13.90% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.97 | 0.96 | 3.94 | 4.39 |
| 7 Days Ago | 0.96 | 0.98 | 3.77 | 4.14 |
| 30 Days Ago | 0.92 | 0.95 | 3.77 | 4.12 |
| 60 Days Ago | 0.92 | 0.95 | 3.77 | 4.12 |
| 90 Days Ago | 0.9 | 0.89 | 3.68 | 4.07 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 1 | 1 |
| Up Last 30 Days | 2 | 1 | 3 | 4 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | 1 | 3 | 2 |
Growth Estimates
| CURRENCY IN USD | RPRX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 15.50% | -- | -- | 8.30% |
| Next Qtr. | 21.50% | -- | -- | 11.90% |
| Current Year | -12.40% | -- | -- | 5.60% |
| Next Year | 11.40% | -- | -- | 13.00% |
| Next 5 Years (per annum) | 3.20% | -- | -- | 11.05% |
| Past 5 Years (per annum) | 41.66% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | B of A Securities: Buy to Buy | 4/12/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 2/20/2024 |
| Maintains | Goldman Sachs: Buy to Buy | 2/20/2024 |
| Maintains | Morgan Stanley: Overweight to Overweight | 11/9/2023 |
| Maintains | Morgan Stanley: Overweight to Overweight | 10/11/2023 |
| Maintains | Morgan Stanley: Overweight to Overweight | 8/9/2023 |
Related Tickers
CYTK Cytokinetics, Incorporated
60.06
+3.75%
ARGX argenx SE
358.05
-0.40%
BBIO BridgeBio Pharma, Inc.
29.08
+2.04%
SPRO Spero Therapeutics, Inc.
1.6180
-1.95%
LEGN Legend Biotech Corporation
44.23
+2.93%
ROIV Roivant Sciences Ltd.
11.24
+0.54%
GMAB Genmab A/S
29.45
+0.98%
FULC Fulcrum Therapeutics, Inc.
7.81
+6.26%
HALO Halozyme Therapeutics, Inc.
43.93
+0.73%
IONS Ionis Pharmaceuticals, Inc.
38.43
-0.97%